Current treatments for chronic hand eczema (CHE) generally fall into two buckets: Either they battle inflammation but lead to unwanted side effects with long-term use or they soothe external symptoms ...
Investor's Business Daily on MSN
Evommune nearly doubles — has Dupixent met its match in eczema?
IPO stock Evommune roughly doubled Tuesday on positive results for its intravenously infused eczema treatment.
Kymera drug positioned to rival Sanofi and Regeneron’s Dupixent succeeds in early-stage eczema trial
Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Kymera Therapeutics reported on Monday that, for the second time this year, it has ...
Sean, a 17-year-old athlete, has struggled with eczema since he was a toddler. Being outdoors in the heat worsens the rash and itch. He is very self conscious about going out with short sleeve shirts ...
A Nektar Therapeutics drug has met the skin clearance goals of a closely watched mid-stage clinical trial in atopic dermatitis. While these preliminary results bring validation to the therapy’s novel ...
Evommune has aced its first major test as a public company, reporting phase 2a eczema data that caused its share price to jump 75% in premarket trading. The biotech, which went public late last year, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results